Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:32:10 EST Tue 02 Dec 2025
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - https://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q0.11.03·1.060.31.032.14    3.3899  0.661108:01:11Nov 2515 min RT 2¢

Recent Trades - All 4 today
Time ETExPriceChangeVolume
08:01:11Q1.05840.02841
08:00:08Q1.070.0419
08:00:04Q1.060.035
08:00:04Q1.070.041
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-11-25 08:00U:FATENews ReleaseFate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
2025-11-13 08:30U:FATENews ReleaseFate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
2025-11-04 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-10-26 11:30U:FATENews ReleaseFate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
2025-10-14 08:00U:FATENews ReleaseFate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
2025-10-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-09-03 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-08-25 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming Investor Conferences
2025-08-12 16:01U:FATENews ReleaseFate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
2025-08-05 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-07-03 13:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-06-11 09:00U:FATENews ReleaseFate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
2025-05-30 16:30U:FATENews ReleaseFate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
2025-05-28 17:54U:FATENews ReleaseFate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
2025-05-13 16:01U:FATENews ReleaseFate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
2025-05-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-04-29 09:26U:FATENews ReleaseFate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
2025-04-14 08:00U:FATENews ReleaseFate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
2025-04-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-03-05 16:01U:FATENews ReleaseFate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates